Lineage Cell Therapeutics (LCTX) Cash from Investing Activities (QoQ) (2010 - 2026)
Lineage Cell Therapeutics (LCTX) Cash from Investing Activities (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Lineage Cell Therapeutics | 254.83 Mn | 192.11 Mn | 1.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 84.83% |
| Dec 31, 2025 | -127,683.33% |
| Sep 30, 2025 | 14.29% |
| Jun 30, 2025 | -100.74% |
| Mar 31, 2025 | -27.78% |
| Dec 31, 2024 | -32.23% |
| Sep 30, 2024 | 144.22% |
| Jun 30, 2024 | -23,039.47% |
| Mar 31, 2024 | -100.39% |
| Dec 31, 2023 | 359.10% |
| Sep 30, 2023 | -88.92% |
| Jun 30, 2023 | 24.20% |
| Mar 31, 2023 | 402.35% |
| Dec 31, 2022 | 87.53% |
| Sep 30, 2022 | -42,079.38% |
| Jun 30, 2022 | -110.87% |
| Mar 31, 2022 | 68.49% |
| Dec 31, 2021 | -114.71% |
| Sep 30, 2021 | 40.87% |
| Jun 30, 2021 | -101.14% |